Current Report Filing (8-k)
AND EXCHANGE COMMISSION
to Section 13 OR 15(d) of the
Exchange Act of 1934
of Report (Date of earliest event reported): May 15,
Jaffe Laboratories, Inc.
name of registrant as specified in its charter)
or other jurisdiction
of principal executive offices) (Zip Code)
telephone number, including area code)
name or former address, if changed since last
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
registered pursuant to Section 12(b) of the Act:
of each class
of each exchange on which registered
Stock, par value $0.00001 per share
NASDAQ Stock Market LLC
to Purchase Common Stock
NASDAQ Stock Market LLC
by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
growth company ☒
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
May 15, 2020, Hancock Jaffe Laboratories, Inc. (“we,” “us,” “our,”
and the “Company”) determined that it will be unable to timely file
its Quarterly Report on Form 10-Q for the fiscal quarter ended
March 31, 2020 (the “Quarterly Report”) as a result of the outbreak
in the United States of the novel coronavirus, COVID-19. In
accordance with the order (the “Order”) promulgated by the
Securities and Exchange Commission on March 25, 2020 in Release No.
34-88465 relating to the Securities Exchange Act of 1934, as
amended, the Company will file its Quarterly Report within 45
calendar days of the date of this report, though the Company
expects to file its Quarterly Report much earlier, on or about May
Company is unable to file the Quarterly Report in a timely manner
because the Company is currently experiencing a significant impact
from the coronavirus outbreak in the United States. Specifically,
the Company has been following the recommendations of local
government and health authorities to minimize exposure risk for its
employees for the past several weeks, including having employees
work remotely, and, as a result, the Quarterly Report will not be
completed by the filing deadline, due to insufficient time to
facilitate the internal and external review process. Below is a
risk factor regarding the coronavirus that the Company’s
stockholders and potential investors in the Company should consider
with respect to the quarter ended March 31, 2020.
The coronavirus pandemic has significantly negatively impacted our
coronavirus pandemic has disrupted the global economy and has
negatively impacted large populations including people and
businesses that may be directly or indirectly involved with the
operation of our company and the manufacturing, development, and
testing of our product candidates. The full scope and economic
impact of the coronavirus is still unknown and there are many risks
from the coronavirus that could generally and negatively impact
economies and healthcare providers in the countries where we do
business, the medical device industry as a whole, and development
stage, pre-revenue companies such as our company. At this time, we
have identified the following coronavirus related risks that we
believe have a greater likelihood of negatively impacting our
company specific, including, but not limited to:
State and local shelter-in-place directives which limit our
employees from accessing our facility to manufacture, develop and
test our product candidates.
restrictions and quarantine requirements which prevent us from
initiating and continuing animal studies and patient trial both
inside and outside of the United States.
burden on hospitals and medical personnel resulting in the
cancellation of non-essential medical procedures such as surgical
procedures needed to implant our product candidates for
pre-clinical and clinical trials.
in the procurement of certain supplies and equipment that are
needed to develop and test our product candidates.
of the capital markets which make it more difficult to obtain the
financing that we need to fund and continue our
back-log at regulatory agencies such as the FDA which may result in
delays in obtaining regulatory approvals.
restrictions which prevent patients from participating and
continuing the participation in clinical trials.
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
JAFFE LABORATORIES, INC.
May 15, 2020
Robert A. Berman